Inclusion Criteria:

1. Adolescents ≥ 12 to < 18 years of age at screening

2. Participant and parent(s)/caregiver(s) or legally acceptable representative willing
and able to give in-formed consent and assent, as required, prior to study
enrollment and to comply with study procedures.

3. Participants of childbearing potential (defined as any participant who has
experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral
tubal ligation, or bilateral oophorectomy] or post-menopausal [defined as amenorrhea
≥ 12 consecutive months]) must agree to be heterosexually inactive from at least 28
days prior to enrollment and through the end of the study OR agree to consistently
use a medically acceptable method of contraception listed below from ≥ 28 days prior
to enrollment and through the end of the study.

4. Is medically stable, as determined by the investigator (based on review of health
status, vital signs [to include body temperature], medical history, and targeted
physical examination [to include body weight]). Vital signs must be within medically
acceptable ranges prior to the vaccination.

5. Agrees to not participate in any other SARS-CoV-2 prevention or treatment trials for
the duration of the study.

6. Have previously received ≥ 2 doses of the Moderna and/or Pfizer-BioNTech monovalent
and/or bivalent COVID-19 vaccines with the last dose having been given ≥ 90 days
previously prior to study vaccination.

Exclusion Criteria:

1. Received COVID-19 vaccines other than Moderna and/or Pfizer-BioNTech in the past,
inclusive of clinical trial COVID-19 vaccines.

2. Participation in research involving receipt of investigational products
(drug/biologic/device) within 90 days prior to study vaccination.

3. Received influenza vaccination within 14 days prior to study vaccination.

4. Received any vaccine ≤ 45 days prior to study vaccination, except for rabies, human
papilloma virus (HPV), tetanus-diphtheria (Td), tetanus, diphtheria, and pertussis
(TDaP/DTap), hepatitis B virus (HBV), and meningococcal vaccines which may be given
as medically indicated.

5. Any known allergies to products contained in the investigational product.

6. Any history of anaphylaxis to any prior vaccine.

7. Autoimmune or immunodeficiency disease/condition (iatrogenic or congenital)
requiring ongoing immunomodulatory therapy.

8. Chronic administration (defined as > 14 continuous days) of immunosuppressant,
systemic glucocorticoids, or other immune-modifying drugs within 90 days prior to
study vaccination.

An immunosuppressant dose of glucocorticoid is defined as a systemic dose ≥ 10 mg of
prednisone per day or equivalent. The use of topical or intranasal glucocorticoids
is permitted. Topical tacrolimus and ocular cyclosporin are permitted.

9. Received immunoglobulin, blood-derived products, or immunosuppressant drugs within
90 days prior to study vaccination, except for rabies immunoglobulin which may be
given if medically indicated.

10. Active cancer (malignancy) on therapy within 3 years prior to study vaccination
(with the exception of adequately treated non-melanomatous skin carcinoma or lentigo
maligna and uterine cervical carcinoma in situ without evidence of disease, at the
discretion of the investigator).

11. Participants who are breastfeeding, pregnant, or who plan to become pregnant prior
to the end of study.

12. Suspected or known history of alcohol abuse or drug addiction within 2 years prior
to the study vaccine dose that, in the opinion of the investigator, might interfere
with protocol compliance.

13. Any other condition that, in the opinion of the investigator, would pose a health
risk to the participant if enrolled or could interfere with evaluation of the study
vaccine or interpretation of study results (including neurologic or psychiatric
conditions likely to impair the quality of safety reporting).

14. Study team member or immediate family member of any study team member (inclusive of
Sponsor, clinical research organization [CRO], and study site personnel involved in
the conduct or planning of the study).

15. Participants with a history of myocarditis or pericarditis.

16. Respiratory symptoms in the past 3 days (ie, cough, sore throat, difficulty
breathing).

17. Temperature of > 38°C within 24 hours of planned study vaccination (site measured or
participant measured).

18. Blood pressure of ≥ 160/100 mmHg.